Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.71 |
| ▸ | BCHE | P06276 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.56 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21427198 | 1.00 | SLC2A1 (0.71) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| Hydrochloric Acid SCHEMBL29051153 | 0.99 | SLC2A1 (0.70) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| Hydrochloric Acid SCHEMBL30467188 | 0.99 | SLC2A1 (0.70) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| SCHEMBL21426904 | 0.95 | SLC2A1 (0.62) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| SCHEMBL21410029 | 0.94 | SLC2A1 (0.70) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| SCHEMBL30467194 | 0.94 | SLC2A1 (0.70) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| Hydrochloric Acid SCHEMBL21410031 | 0.94 | SLC2A1 (0.61) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| Hydrochloric Acid SCHEMBL21410028 | 0.93 | SLC2A1 (0.68) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| SCHEMBL21410033 | 0.93 | SLC2A1 (0.68) | SLC2A1BCHESMN1; SMN2LMNAHTT | |
| SCHEMBL30467196 | 0.93 | SLC2A1 (0.68) | SLC2A1BCHESMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105598-B | Compounds for preventing or treating obesity or metabolic syndrome and pharmaceutical compositions comprising the same | 普罗泰克株式会社 | 2023-06-27 | — | — | CN | claimed |
| CN-112424160-B | Novel P62 ligand compound and composition for preventing, improving or treating protein conformational diseases comprising the same | 奧土择破利悟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-112105598-B | Compounds for preventing or treating obesity or metabolic syndrome and pharmaceutical compositions comprising the same | 普罗泰克株式会社 | 2023-06-27 | — | — | CN | disclosed |
| US-20220323379-A1 | P62 LIGAND COMPOUND AND ER-PHAGY-PROMOTING USE THEREOF | Protech, Inc. (KR) | 2022-10-13 | — | — | US | disclosed |
| CN-114641282-A | P62 ligand compound and ER-autophagy promoting use thereof | 普罗泰克株式会社 | 2022-06-17 | — | — | CN | disclosed |
| EP-3988090-A1 | P62 LIGAND COMPOUND AND ER-PHAGY-PROMOTING USE THEREOF | Protech Inc. (KR) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323379-A1 | P62 LIGAND COMPOUND AND ER-PHAGY-PROMOTING USE THEREOF | SQSTM1, ATG7, TFEB | SLC2A1 2992/4885BCHE 4621/4885SMN1; SMN2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.